Monoclonal Antibody to CD20 2017-03-03T15:57:19+00:00

December 16, 2010

A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

  • Study Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
  • Start Date: 8/2010
  • End Date: 12/2013
  • Design: Placebo-controlled
  • Age range (years): from 18 to 70
  • Type of PH
    • Systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH)
  • Study Duration for individual partient: 52 weeks
  • Listing on